ARGAH1 Antibody

Overview of Arginase 1 (ARG1) Antibodies

ARG1 antibodies target the enzyme arginase 1, a 35–40 kDa metalloprotein critical in urea metabolism and immune regulation . Key characteristics include:

Applications of ARG1 Antibodies

ARG1 antibodies are used across diverse research and diagnostic applications:

Immunohistochemistry (IHC)

• Detects hepatocellular carcinoma (HCC) with high specificity .

• Labels hepatocytes in normal tissues and granulocytes in peripheral blood .

Western Blot (WB)

• Identifies ARG1 at ~40 kDa in human, mouse, and rat liver lysates .

• Buffer conditions: Reducing agents (e.g., β-mercaptoethanol) enhance trimer detection .

Flow Cytometry

• Stains ARG1 in HepG2 hepatocellular carcinoma cell lines (e.g., Clone MAB58681) .

Immune Modulation Studies

• Inhibitory antibodies (e.g., CB-1158) block ARG1 activity, restoring CD8+ T cell function in pancreatic cancer .

Role in Immune Suppression

• Tumor Microenvironment (TME): Myeloid-derived ARG1 depletes arginine, inhibiting T cell activation .

• Therapeutic Targeting:

  • ARG1 inhibitors (e.g., CB-1158) enhance anti-PD1 efficacy in pancreatic cancer .

  • Anti-ARG1 vaccines shift macrophages to proinflammatory M1 phenotypes, improving tumor control .

Neurological Functions

• Microglia Subtype: ARG1+ microglia in the basal forebrain regulate cholinergic innervation and dendritic spine maturation .

• Knockout models show cognitive deficits in female mice, linking ARG1 to synaptic plasticity .

Clinical and Preclinical Relevance

• Biomarker Potential: ARG1 overexpression correlates with poor prognosis in liver and pancreatic cancers .

• Combination Therapies: ARG1 blockade synergizes with checkpoint inhibitors (e.g., anti-PD1) to reduce tumor growth .